What happened with ECL today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Factories need to keep process water and production equipment working properly; restaurants, hotels and hospitals need to keep dishes, linens and facilities clean. Ecolab supplies the chemicals, dispensing equipment and technical support for those tasks. Water treatment and industrial cleaning form its largest business, followed by cleaning and sanitizing for foodservice and other commercial facilities; together they account for most revenue.
Most customers pay for products and equipment rather than services alone. Ecolab’s field-sales staff also advise customers on their use, and distributors supply some markets. Its 3D TRASAR water-treatment technology combines chemicals with remote monitoring and control. Restaurant and food-retail programs use Ecolab and Kay cleaning products, while some customers lease dishwashing machines bundled with chemicals and maintenance. Smaller businesses provide pest-control services and cleaning and contamination control for pharmaceutical and personal-care manufacturers.
Ecolab is not materially dependent on any single customer overall, but its Specialty business relies heavily on a limited group of major restaurant chains, franchisees and food retailers. Demand depends on customers’ operating activity and their need to treat water and maintain hygiene. Rules governing chemical manufacturing, product registration, sale and use also shape what it can supply.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
These peers cover only part of Ecolab, whose results depend chiefly on industrial water-treatment demand and cleaning consumption in foodservice, hospitality and food processing.
Clorox competes with Ecolab for professional customers buying cleaning, sanitation and infection-prevention products, rather than across Ecolab’s whole business. Watch CloroxPro and Clorox Healthcare news for competition facing Ecolab’s institutional cleaning products.
STERIS competes with Ecolab in cleaning, infection prevention and contamination control, selling products, equipment and services to healthcare and drug manufacturers. Its pharmaceutical contamination-control offerings are the part to watch for competition facing Ecolab’s Life Sciences business.
Rollins competes with Ecolab for pest-control contracts from foodservice, healthcare and other workplaces, inspecting properties, treating infestations and preventing pests. Its commercial-account wins matter more to this comparison than its residential pest and termite business.
Danaher competes with Ecolab in materials sold to biopharmaceutical manufacturers to purify their products: Cytiva purification resins rival Ecolab’s Purolite resins.
Danaher Corporation earningsDHR
Danaher’s report can offer a read on biopharma customers’ demand for purification products, where its Cytiva resins compete with Ecolab’s Purolite resins.
Look at sales and demand commentary for Danaher’s biopharma business. Strength would suggest firmer demand in the market for purification products, but would not show that Cytiva resins took business from Purolite. Weakness could point to softer customer demand, but would not identify which resin supplier lost orders. The report helps gauge the market, not Ecolab’s resin share.
Rollins, Inc. earningsROL
Rollins’s report can show whether commercial customers are spending on pest-control services, which it and Ecolab both provide to workplaces such as restaurants and healthcare facilities.
Focus on Rollins’s commentary about commercial pest control, not its residential business. Stronger commercial activity would suggest that demand for the workplace contracts both companies pursue is holding up and competition remains active. Weakness could point to customers cutting spending in that market, leaving Ecolab’s pest business in a softer demand environment. If Rollins does not separate commercial results, its overall figures offer only a limited read.
Ecolab, Inc. earningsThis company
Ecolab’s report will show whether sales volume and pricing are both supporting growth, and whether that growth is widening its operating margin.
Read volume, pricing and adjusted operating margin together. Rising volume, a contribution from pricing and a wider margin would show that customers are buying more and Ecolab is turning growth into more profit. If volume is weak and the margin narrows, sales growth driven by pricing would rest on a weaker base, pointing to soft demand or higher costs to serve customers.
Fed Interest Rate Decision
The Fed’s decision tracks the U.S. economy’s benchmark borrowing rate; changes can raise or lower Ecolab’s interest costs on floating-rate debt and new borrowing.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can increase interest expense on Ecolab’s floating-rate debt and make borrowing to fund operations, investment or acquisitions more costly.
If it comes in below expectations
Lower rates can ease interest expense on Ecolab’s floating-rate debt and reduce the cost of borrowing for operations, investment or acquisitions.
STERIS plc earningsSTE
STERIS’s report can show pharmaceutical manufacturers’ demand for contamination-control products and services in an area where it competes with Ecolab’s Life Sciences business.
Look at sales and customer-demand commentary for STERIS’s Life Sciences business. Stronger demand would suggest pharmaceutical manufacturers are sustaining purchases of contamination-control products and services, supporting the market Ecolab’s Life Sciences business also serves. Weaker demand could mean customers are spending less, but would not prove that STERIS took Ecolab’s customers. The takeaway is the direction of shared-market demand, not a change in market share.
